Gerard D. Wright and Paul R. Thompson

Department of Biochemistry, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5

TABLE OF CONTENTS

1. Abstract

2. Introduction

3. Aminoglycoside kinases (APHs)

3.1. Nomenclature
3.2. APH(3’)

3.2.1. APH(3’) from clinical isolates
3.2.2. APH(3’) from antibiotic producing organisms

3.3. Other Aminoglycoside Kinases

3.3.1.APH(2")
3.3.2.APH(3") and APH(6)
3.3.3.APH(9)
3.3.4. APH(4)
3.3.5. APH(7")
3.3.6. Other aminoglycoside and miscellaneous phosphotransferases
3.3.7. Mycobacterial APHs

3.4. Phylogenetic relationship between APHs

4. APH(3’)-IIIa Structure and Mechanism

5. Inhibition of APHs

6. Evolution of APHs

7. Acknowledgments

8. References

1. ABSTRACT

Aminoglycoside antibiotics constitute an important class of clinically useful drugs which are imperiled by the emergence of resistant organisms. Aminoglycoside resistance in the clinics is primarily due to the presence of modifying enzymes which N-acetylate, O-adenylate or O-phosphorylate the antibiotics. The latter family of enzymes are termed the aminoglycoside phosphotransferases or kinases and are the subject of this review. There are seven classes of aminoglycoside phosphotransferases (APH(3’), APH(2"), APH(3"), APH(6), APH(9), APH(4), APH(7")) and many isozymes in each class, and although there is very little overall general sequence homology among these enzymes, certain signature residues and sequences are common. The recent determination of the three-dimensional structure of the broad spectrum aminoglycoside kinase APH(3’)-IIIa complexed with the product ADP, in addition to mechanistic and mutagenic studies on this and related enzymes, has added a great deal to our understanding of this class of antibiotic resistance enzyme. In particular, the revelation of structural and mechanistic similarities between APHs and Ser/Thr and Tyr kinases has set the stage for future inhibition studies which could prove important in reversing aminoglycoside resistance.